Market Overview

Pfizer Reports Data for XELJANZ in RA, Says Data Included Up to Five Years Open Label, Safety, Efficacy


Pfizer Inc. (NYSE: PFE) announced today that 20 abstracts for XELJANZ®
(tofacitinib citrate), the first in a new class for the treatment of
rheumatoid arthritis (RA), oral Janus kinase (JAK) inhibitors, will be
presented at the American College of Rheumatology (ACR) / Association of
Rheumatology Health Professionals (ARHP) 2013 Annual Meeting, which is
being held October 25-30 in San Diego, CA. XELJANZ is approved in the
United States for the treatment of adults with moderately to severely
active RA who have had an inadequate response or intolerance to
methotrexate, at a dose of 5 mg tablet twice daily.

These data add to the understanding of the efficacy and safety profile
of XELJANZ in the treatment of RA. XELJANZ was studied in

See full press release

Posted-In: News


Related Articles (PFE)

View Comments and Join the Discussion!

Partner Center